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Hepatitis C virus (HCV) core protein can form capsid-like particles and is believed to be the viral capsid protein. Besides
its structural functions, this protein is also known to possess multiple regulatory functions. In this article, we have studied
the possible phosphorylation of HCV core protein in two different human liver-derived cell lines Huh7 and HepG2. Our results
indicated that the HCV core protein could be phosphorylated, albeit inefficiently, independent of its downstream E1 protein
in these two cell lines. Two of the basal phosphorylation sites were identified to be serine-53 and serine-116. The
phosphorylation of the core protein could be enhanced by the PKC activator phorbol 12-myristic 13-acetate (PMA), and the
PKA activator forskolin, and these enhancements could be abolished by the respective inhibitors of PKC and PKA, indicating
that the core protein is a substrate of these two kinases. While both serine-53 and serine-116 served as the PKC
phosphorylation sites, serine-116 appeared to be the major PKA phosphorylation site. Further analyses using serine-to-
alanine mutation to mimic dephosphorylation and serine-to-aspartic acid mutation to mimic phosphorylation revealed that the
conversion of serine-116 to aspartic acid led to an enhanced nuclear localization of the core protein. This observationINTRODUCTION
Hepatitis C virus (HCV) can cause severe liver dis-
eases including acute and chronic hepatitis, liver cirrho-
sis, and hepatocellular carcinoma (Management of Hep-
atitis C, 1997; Lefkowitch et al., 1993; Scheuer et al.,
1992). This virus is an enveloped virus with a positive-
stranded RNA genome of about 9.6 kb. The HCV
genomic RNA contains a long open reading frame that
codes for a polyprotein with a length of slightly more than
3000 amino acids. This polyprotein is cleaved by viral
and cellular proteases to generate at least 10 protein
products. The structural proteins, which include the core
protein and E1 and E2 envelope proteins, are located at
the amino-terminus of the polyprotein sequence. The p7
protein follows the E2 protein sequence. It may or may
not be separated from the E2 protein during the cleavage
of the HCV polyprotein (Dubuisson and Rice, 1996; Lin et
al., 1994; Mizushima et al., 1994). The nonstructural pro-
teins, which include NS2, NS3, NS4A, NS4B, NS5A, and
NS5B, follow the p7 sequence and are located at the
carboxyl-terminus of the polyprotein sequence (Grakoui
et al., 1993; Hijikata et al., 1991, 1993; Shimotohno et al.,
1995).
The core protein is 191 amino acids long with a rela-
tive molecular mass of about 21K (p21c). The carboxyl-© 2002 Elsevier Science (USA)
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20terminus of this protein is hydrophobic and contains a
signal sequence to target its following E1 envelope pro-
tein to the membrane of the endoplasmic reticulum (ER).
The separation of the core protein from its following E1
envelope protein sequence is mediated by the signal
peptidase located in the ER lumen (Hijikata et al., 1991;
Santolini et al., 1994). The core protein can undergo a
secondary cleavage, possibly mediated by the cellular
signal peptide peptidase activity (Hussy et al., 1996),
which removes its carboxyl-terminal sequence. This
truncated core protein has a relative molecular mass of
about 19K (p19c). It comigrates on the gel with the core
protein truncated at amino acid 173 and is estimated to
be 173 amino acids in length (Liu et al., 1997; Yasui et al.,
1998). The p19c core protein is the major core protein
species detected in mammalian cells in the expression
studies and in the HCV virion (Liu et al., 1997; Yasui et al.,
1998). It likely represents the mature core protein product
(Yasui et al., 1998). When the HCV core protein is ex-
pressed in mammalian cells, it is found predominantly in
the cytoplasm in association with the membranes
(Chang et al., 1994; Liu et al., 1997; Lo et al., 1995;
Santolini et al., 1994; Selby et al., 1993). However, the
core protein has also been detected in the nucleus (Liu
et al., 1997; Yasui et al., 1998). The cytoplasmic core
protein and the nuclear core protein are recognized by
distinct monoclonal antibodies, suggesting their struc-
tural differences. The HCV core protein can dimerize,indicates that one function of phosphorylation may be to re
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and this dimerization process may be important for the
formation of the viral capsid (Lo and Ou, 1998; Matsu-gulate
moto et al., 1996; Nolandt et al., 1997; Yan et al., 1998).
The HCV core protein expressed in Escherichia coli
could form capsid-like particles (Kunkel et al., 2001) and
the HCV structural proteins expressed in sf9 insect cells
had been found to form virus-like particles (Baumert et
al., 1998). In addition to its structural functions, the HCV
core protein has also been shown to possess regulatory
functions. It can regulate signaling pathways and induce
apoptosis and oncogenesis (for reviews, see Choi et al.,
2001; Lai and Ware, 2000).
The HCV core protein truncated at its carboxyl-termi-
nus could be phosphorylated in insect cells (Lanford et
al., 1993). In a related study, it was found that the HCV
core protein synthesized in vitro using the rabbit reticu-
locyte lysates could also be phosphorylated by protein
kinase C (PKC) and protein kinase A (PKA) (Shih et al.,
1995). By conducting the mutagenesis studies in vitro,
Shih et al. (1995) further suggested that the PKC phos-
phorylation sites in the core protein were the serine
residues located at amino acids 53 and 99 (serine-53
and serine-99), and the PKA sites were the serine resi-
dues located at amino acids 53 and 116 (serine-53 and
serine-116) (Shih et al., 1995). Despite these insect cell
and in vitro studies, whether the HCV core protein is
indeed a phosphoprotein in mammalian cells remains to
be determined. In this article, we have investigated
whether the HCV core protein can be phosphorylated in
liver-derived cell lines. Our results indicated that the HCV
core protein could be inefficiently phosphorylated by 32P
in Huh7 cells and HepG2 cells, two well-differentiated
human liver cell lines. This phosphorylation could be
suppressed by PKC and PKA inhibitors and enhanced by
PKC and PKA activators, confirming a role of these two
kinases in the core protein phosphorylation. Further
studies identified serine-53 and serine-116 as the major
PKC phosphorylation sites and serine-116 as the major
PKA phosphorylation site. By mutating these serine res-
idues to alanine to mimic dephosphorylation and to as-
partic acid to mimic phosphorylation, we found that the
mutation of serine-116 to aspartic acid could facilitate the
nuclear localization of the core protein. This observation
suggests a role of phosphorylation of serine-116 in the
regulation of nuclear localization of the core protein.
RESULTS
Phosphorylation of the core protein in Huh7 cells
To study whether the HCV core protein is a phospho-
protein in cells, we have expressed it in Huh7 cells, a
well-differentiated human hepatoma cell line, and per-
formed the 32P-radiolabeling experiment. Since none of
our antibodies could efficiently immunoprecipitate the
core protein, the HA-tag, a sequence derived from the
influenza virus HA protein, was fused to the amino-
terminus of the core protein to facilitate the analysis. This
tag does not contain any serine or threonine residue for
phosphorylation. Huh7 cells were transfected with pC-
DEF/HA-RC, a DNA plasmid that expressed the HA-
tagged core protein. Two days after transfection, Huh7
cells were labeled with 32P-orthophosphate and the core
protein was immunoprecipitated with the anti-HA anti-
body. As shown in Fig. 1A, a protein band with a molec-
ular weight of approximately 22 kDa, the predicted mo-
lecular weight of the HA-core fusion protein was labeled
by 32P and immunoprecipitated by the anti-HA antibody.
This protein band, which could also be detected by
Western blot using the anti-core antibody (Fig. 1B), was
not detected in the cells transfected by the control ex-
pression vector. A similar result was obtained when
Huh7 cells were replaced by HepG2 cells, a human
hepatoblastoma cell line (data not shown). These results
indicated that the HCV core protein could indeed be
phosphorylated in liver cells. The phosphorylation of the
core protein was not affected when it was coexpressed
with its downstream E1 envelope protein sequence
(Fig. 2).
Despite its ability to be phosphorylated, the phosphor-
ylation efficiency of the HCV core protein in Huh7 cells
appeared to be very low when compared with the hep-
atitis B virus (HBV) core protein, which is a capsid protein
of similar size. As shown in Fig. 3, when the HBV core
protein was metabolically labeled with 32P-orthophos-
phate and [35S]methionine separately followed by radio-
immunoprecipitation, the relative 32P-to-35S signal of this
protein was approximately 5:1. This result is consistent
with our previous observations (Liao and Ou, 1995; Yeh
and Ou, 1991). However, when the same experiment was
repeated with the HCV core protein, the relative 32P-to-35S
ratio was approximately 1:6. Since both the HBV core
FIG. 1. Phosphorylation of HCV core protein in Huh7 cells. (A) Ra-
dioimmunoprecipitation of the core protein. (B) Western blot analysis of
the core protein. Huh7 cells were transfected with the control pCDEF
vector (Lane 1) or with pCDEF/HA-RC (Lane 2) and split into two plates
the second day after transfection. One plate was labeled with 32P-
orthophosphate on the third day and the core protein was then immu-
noprecipitated with the monoclonal anti-HA antibody (USC Cell Culture
Core Facility) and analyzed by SDS–PAGE. The other plate was also
lysed on the third day for Western blot analysis using the rabbit
anti-core antibody (Lo et al., 1995; Lu et al., 1999). Details of the
experimental procedures are described under Materials and Methods.
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protein and the HCV core protein have two methionine
residues in their sequences, the phosphorylation effi-
ciency of the HCV core protein was 30 times lower than
that of the HBV core protein.
Phosphorylation of the core protein by PKC and PKA
To investigate the possible role of PKC in the phos-
phorylation of the HCV core protein in vivo, Huh7 cells
transfected by the core protein-expressing plasmid were
treated with the PKC inhibitor calphostin C. As shown in
Fig. 4A, treating the cells with calphostin C did not affect
the overall expression level of the core protein, as re-
vealed by the Western blot analysis. However, the phos-
phorylation signal of the core protein was reduced by
approximately one-half with 1 M calphostin C (Figs. 4A
and 4D), suggesting a possible role of PKC in the phos-
phorylation of the core protein. This possibility was sup-
ported by the observation that the phosphorylation of the
core protein could be enhanced by the PKC activator
phorbol 12-myristic 13-acetate (PMA). As shown in Fig.
4B, treating the cells with PMA led to an increase of the
phosphorylation signal of the core protein. This increase
of signal was positively correlated with the length of time
of the PMA treatment, with the signal peaked at 45 min.
Similarly, we had also performed the Western blot anal-
ysis, which revealed that the core protein expression
was not affected by the PMA treatment during the time
period of the study. To ensure that the increase of the
core protein phosphorylation signal by PMA was indeed
due to PKC, we also treated cells with Ro-31-8220 (Ro),
another inhibitor of PKC. As shown in Fig. 4C, the induc-
tion of the core protein phosphorylation was abolished if
cells treated with PMA were pretreated with Ro. Similar
results were obtained if Ro was replaced with calphostin
C (data not shown). These results indicated that PKC
could indeed phosphorylate the core protein. The phos-
phorylation results were quantified and shown in Fig. 4D.
To investigate whether the HCV core protein could
also be phosphorylated by PKA in Huh7 cells, cells
transfected by pCDEF/HA-RC were treated with forsko-
lin, a PKA activator. As shown in Fig. 5A, the treatment of
Huh7 cells with an increasing concentration of forskolin
led to an increasing level of the core protein phosphor-
ylation. Similarly, the Western blot control experiment
revealed no difference of the core protein expression
level with or without forskolin treatment. These results
suggested that PKA could also phosphorylate the core
protein. This speculation was again confirmed by a sep-
arate experiment, in which the PKA inhibitor H-89 was
found to abolish the phosphorylation induced by forsko-
lin (Fig. 5B). The PKA phosphorylation results were quan-
tified and shown in Fig. 5C.
FIG. 3. Comparison of the phosphorylation efficiencies of HBV and
HCV core proteins. Huh7 cells were transfected with various DNA
plasmids by the CaPO4 precipitation method, split into two plates the
second day after transfection, and metabolically labeled with 32P-or-
thophosphate (top) or [35S]methionine (bottom) on the third day. The cell
lysates were then immunoprecipitated with the anti-HBV core antibody
(Liao and Ou, 1995; Yeh and Ou, 1991) (A) or the anti-HA antibody (B).
(A) Lane 1, cells were transfected with the pRc/CMV control vector
(Invitrogen); Lane 2, cells were transfected with pCMV-core, a plasmid
that expressed the HBV core protein (Liao and Ou, 1995; Yeh and Ou,
1991). (B) Lane 1, cells were transfected with the pCDEF control vector;
Lane 2, cells were transfected with pCDEF/HA-RC, which expressed
the HCV core protein. The locations of the HBV core protein (HBcAg)
and the HA-tagged HCV core protein (HA-core) are marked. In (A), the
relative ratio of 32P-labeled and 35S-labeled HBV core protein signals as
measured by a densitometer was approximately 5:1. In (B), the relative
ratio for 32P-labeled and 35S-labeled HCV core protein signals was 1:3.
However, since twice the amount of the 32P-labeled HCV core protein
was loaded in the top panel of (B) to enhance its signal, the actual
relative ratio of 32P-labeled and 35S-labeled HCV core protein was 1:6.
FIG. 2. Phosphorylation of the HCV core protein in the presence of its
downstream E1 envelope protein. Huh7 cells were transfected with the
pCDEF vector (Lane 1), pCDEF/HA-RC, which expressed the HA-
tagged core protein (Lane 2), or pCDEF/HA-RCE, which expressed the
core-E1 coding sequence together (Lane 3). Twenty-four hours after
transfection, cells were split into two 60-mm dishes and labeled with
32P-orthophosphate or [35S]methionine as described under Materials
and Methods. While the total lysates of 32P-labeled cells were immu-
noprecipitated for the core protein using the anti-HA antibody (top), the
[35S]methionine-labeled cell lysates were split equally into two tubes for
immunoprecipitation of the core protein using the anti-HA antibody
(middle), or for immunoprecipitation of the E1 envelope protein using 2
l of the serum isolated from an HCV patient (bottom). The locations of
HA-core and E1 proteins are marked.
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Identification of the PKA and PKC phosphorylation
sites in the core protein
Based on their in vitro mutagenesis and phosphoryla-
tion studies, Shih et al. proposed that serine-53 and
serine-99 constituted the PKC phosphorylation sites, and
serine-53 and serine-116 constituted the PKA phosphor-
ylation sites (Shih et al., 1995). As shown in Fig. 6A,
serine-53, serine-99, and serine-116 are located in the
consensus PKC recognition motifs, and serine-53 and
serine-116 are located in the consensus PKA recognition
motifs (Kemp and Pearson, 1990; Ohno and Suzuki,
1995). To investigate whether serine-53, serine-99, and
serine-116 could indeed serve as the phosphorylation
sites for PKC in vivo, we had mutated them individually to
alanine (Fig. 6B). The mutated core proteins were then
expressed in Huh7 cells. As shown in Figs. 7A and 7B,
the mutation of serine-53 (S53A) or serine-116 (S116A) to
alanine reduced slightly the basal phosphorylation level,
while the mutation of serine-99 (S99A) to alanine did not
apparently affect the basal phosphorylation level. These
results were reproducible in at least three other trans-
fection experiments (also see below).
In agreement with the results shown in Fig. 4, the
treatment of cells transfected by the wild-type core pro-
tein construct with PMA resulted in a nearly threefold
enhancement of the core protein phosphorylation (Figs.
7A and 7C). The level of the core protein phosphorylation
in cells treated with PMA was partially reduced by the
S53A or the S116A mutation but remained about the
same with the S99A mutation (Fig. 7A). These results
indicate that serine-53 and serine-116 are two major PKC
phosphorylation sites and, in contrast to the previous
article (Shih et al., 1995), serine-99 is not a major PKC
phosphorylation site. The possibility that serine-53 and
serine-116 are the two major PKC phosphorylation sites
was confirmed by the studies with the S53A and S116A
FIG. 4. Phosphorylation of HCV core protein by PKC. (A) Suppression of the core protein phosphorylation by calphostin C. Huh7 cells transfected
with the control pCDEF vector (Lane 1) or with pCDEF/HA-RC (Lanes 2–4) were labeled with 32P-orthophosphate as described under Materials and
Methods. During the last hour of 32P-labeling, cells were treated with calphostin C (CalC) at a concentration of 0.5 M (Lane 2) or 1.0 M (Lane 3)
or with DMSO (Lanes 1 and 4). The Western blot result using the anticore antibody is shown at the bottom. This served as a control for monitoring
the expression level of the core protein. HA-core marks the location of the core protein band. (B) Time-dependent phosphorylation of the core protein
induced by PMA. Huh7 cells were transfected with pCDEF (Lane 1) or pCDEF/HA-RC (Lanes 2–6) and labeled with 32P-orthophosphate. Cells were
treated with DMSO for 60 min (Lanes 1 and 2) or with PMA (Aldrich) (Lanes 3–6) for the length of time indicated. Similar to (A), the Western blot result
is shown at the bottom for monitoring the core protein expression level. (C) Suppression of core protein phosphorylation by Ro-31-8220 (Ro). Huh7
cells were transfected with pCDEF (Lanes 1 and 2) or pCDEF/HA-RC (Lanes 3–5), labeled with 32P-orthophosphate for 4 h, treated with 100 ng/ml PMA,
and 1 M Ro (Calbiochem-Novabiochem), as indicated under the gel. For the controls without the treatment of PMA or Ro, DMSO was used instead.
In Lanes 1–4, DMSO or PMA was added during the last hour of 32P-labeling. In Lane 5, cells were treated with Ro for 1 h prior to the PMA treatment.
The Western blot result is shown at the bottom. (D) Histogram of the relative core protein phosphorylation levels. The phosphorylation signals of the
core protein bands shown in (A), (B), and (C) were measured by PhosphorImager, adjusted against the core protein level as determined by the Western
blot, and further normalized against the core protein signal immunoprecipitated from the cells treated with only DMSO. The equation used for
calculation is described under Materials and Methods. The results represent the average of at least three independent transfection experiments.
CalC(0.5) and CalC(1.0), the treatment with 0.5 and 1.0 M Calphostin C, respectively.
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double mutant (S53/116A). As shown in Figs. 7B and 7C,
the ability of the S53/116A double mutant to respond to
PMA for phosphorylation induction was almost entirely
abolished.
Since serine-53 and serine-116 are located in the pu-
tative PKA phosphorylation motifs (Fig. 6), we had also
investigated whether these two sites served as the PKA
phosphorylation sites in vivo. As shown in Fig. 8A, in
agreement with the results shown in Fig. 7A, the basal
phosphorylation levels of S53A and S116A mutants were
slightly lower than that of the wild-type core protein. The
PKA activator forskolin enhanced the core protein phos-
phorylation approximately twofold (Figs. 8A and 8C). Al-
though the S53A mutant was still able to respond to
forskolin for a slightly less than twofold induction of
phosphorylation, the ability of the S116A mutant to re-
spond to forskolin for phosphorylation was greatly dimin-
ished (Figs. 8A and 8C). Similar to the PKC studies, the
S53/116A double mutant displayed no increase in phos-
phorylation after forskolin treatment (Figs. 8B and 8C).
These results indicated that serine-116 served as the
major phosphorylation site for PKA and serine-53 likely
served as the minor PKA phosphorylation site.
Regulation of nuclear localization of the core protein
by phosphorylation
Although the HCV core protein contains a nuclear
localization signal and has been detected in a small
amount in the nucleus (Chang et al., 1994; Liu et al., 1997;
Suzuki et al., 1995; Yasui et al., 1998), the majority of the
core protein is localized to the cytoplasm in association
with the membranes (Chang et al., 1994; Liu et al., 1997;
Lo et al., 1995; Santolini et al., 1994; Selby et al., 1993).
The molecular mechanism that regulates the nuclear
localization of this small amount of the core protein is
unknown. To investigate whether the nuclear localization
of the core protein is regulated by PKC or PKA phosphor-
FIG. 6. Illustration of core protein phosphorylation sites and their
mutations. (A) Putative core protein phosphorylation sites. These sites
were identified based on the consensus PKC recognition sequences,
which are K/RXXS/T and S/TXR/K, and the consensus PKA sequence,
which is RK/RXS/T (Kemp and Pearson, 1990; Ohno and Suzuki, 1995;
Shih et al., 1995). (B) Core protein mutants and their respective mutated
sequences.
FIG. 5. Phosphorylation of the HCV core protein by PKA. (A) Phos-
phorylation of the core protein induced by forskolin. Huh7 cells trans-
fected with pCDEF (Lane 1) or pCDEF/HA-RC (Lanes 2–4) were treated
with DMSO (Lanes 1 and 2) or with 1 M (Lane 3) or 5 M forskolin
(Lane 4) (Calbiochem-Novabiochem) for 30 min prior to the end of
32P-labeling. The core protein was then immunoprecipitated with the
anti-HA antibody. The Western blot result using the rabbit anti-core
antibody is shown at the bottom. Fskl, forskolin. (B) Effects of the PKA
inhibitor H-89 on core protein phosphorylation. Huh7 cells were trans-
fected with pCDEF (Lanes 1–3) or with pCDEF/HA-RC (Lanes 4–6)
followed by 32P-labeling. During labeling, cells were treated with DMSO
(Lanes 1, 2, 4, and 5) or 10 M H-89 (Lanes 3 and 6) for 2 h followed by
treatment with DMSO (Lanes 1 and 4) or 5 M forskolin (Lanes 2, 3, 5,
and 6) for 30 min. The 32P-labeled core protein immunoprecipitated with
the anti-HA antibody is shown on the top and the Western blot result
using the anticore antibody is shown at the bottom. (C) Histogram of
the relative core protein phosphorylation levels. Similar to Fig. 4D, the
results were adjusted based on the Western blot results and normal-
ized against the 32P-signal of the core protein isolated from cells treated
with only DMSO. The results represent the average of at least three
independent experiments.
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ylation, we had treated cells that expressed the core
protein with PMA or forskolin to induce core protein
phosphorylation. The nuclear localization of the core
protein was then examined by indirect immunofluores-
cence staining. Our results revealed no major difference
in the subcellular localization of the core protein with or
without the treatments (data not shown). Since it is likely
that this lack of difference in subcellular localization was
due to the inefficient phosphorylation of the core protein
even in the presence of PKC and PKA activators, we
decided to use the serine-to-alanine mutation to mimic
dephosphorylation and the serine-to-aspartic acid muta-
tion to mimic phosphorylation (Fig. 6B). These dephos-
FIG. 8. Analysis of forskolin-induced phosphorylation of the core
protein mutants. (A) Effects of forskolin on the phosphorylation of the
serine-to-alanine single mutants. Huh7 cells were transfected with
pCDEF (Lanes 1 and 2), pCDEF/HA-RC (Lanes 3 and 4), S53A (Lanes 5
and 6), or S116A (Lanes 7 and 8) DNA construct and treated with DMSO
(odd-number lanes) or forskolin (even-number lanes) for 30 min. (B)
Effects of forskolin on the phosphorylation of the S53/116A double
mutant. Lanes 1–2, cells transfected with pCDEF; Lanes 3–4, cells
transfected with pCDEF/HA-RC; and Lanes 5–6, cells transfected with
the S53/116A DNA construct. Odd-number lanes, cells treated with
DMSO, and even-number lanes, cells treated with forskolin. Western
blot results are shown at the bottom of both (A) and (B). (C) Histogram
of the fold-induction of phosphorylation by forskolin. The phosphoryla-
tion signals of the core protein were measured by a PhosphorImager
and adjusted based on the core protein levels determined by the
Western blot analysis. Fold-induction of phosphorylation was then
calculated by dividing the phosphorylation signal of the core protein in
the presence of forskolin with that in the absence of forskolin.
FIG. 7. Analysis of PMA-induced phosphorylation of the HCV core
protein mutants. (A) Effects of PMA on the serine-to-alanine single
mutants. Huh7 cells were transfected with pCDEF (Lanes 1 and 2),
pCDEF/HA-RC (Lanes 3 and 4), S53A (Lanes 5 and 6), S116A (Lanes 7
and 8), or S99A (Lanes 9 and 10) DNA construct and treated with DMSO
(odd number lanes) or with PMA (even number lanes) during the last
hour of 32P-labeling. The Western blot result using the anticore antibody
is shown at the bottom. (B) Effects of PMA on the phosphorylation of the
S53/116A double mutant. Cells were transfected with pCDEF (Lanes 1
and 2), pCDEF/HA-RC (Lanes 3 and 4), or S53/116A (Lanes 5 and 6) and
treated with DMSO (odd-number lanes) or PMA (even-number lanes)
for 1 h. Similar to (A), the Western blot result is shown at the bottom. (C)
Histogram of the fold-induction of phosphorylation induced by PMA.
The phosphorylation signals of the core protein shown in (A) and (B)
were measured by a PhosphorImager and adjusted against the core
protein levels detected by Western blot. The fold-induction of phosphor-
ylation was then calculated by dividing the phosphorylation signal of
the core protein in the presence of PMA with that in the absence of
PMA.
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phorylated and phosphorylated analogs of the core pro-
tein were expressed in Huh7 cells and their subcellular
localizations were examined again by indirect immuno-
fluorescence staining. The dephosphorylated analogs
S116A (Fig. 9B), S53A, and the S53/116A double mutant
(data not shown) were all found to be localized to the
cytoplasm with a staining pattern similar to that of the
wild-type core protein. While the phosphorylated analogs
FIG. 9. Subcellular localization of the HCV core protein mutants. (A) Subcellular fractionation of Huh7 cells that had been transfected with various
DNA constructs. C, cytoplasmic fraction; N, nuclear fraction. (B) Immunofluorescence staining of the core protein. The procedures for subcellular
fractionation and the subsequent Western blot analysis using the anticore antibody are described under Materials and Methods. Vector, cells
transfected with pCDEF; WT, cells transfected with pCDEF/HA-RC; S116A, cells transfected with the pHA-RC(S116A) construct; S116D, cells
transfected with the pHA-RC(S116D) construct; S53/116D, cells transfected with the pHA-RC(S53/116D) construct. GRP78 and Ku, which are
cytoplasmic protein and nuclear protein, respectively, were also analyzed by Western blot using the anti-GRP78 antibody (Santa Cruz Biotech) and
the mouse anti-Ku antibody (NeoMarkers, Fremont, CA) to serve as the fractionation controls. Cells transfected with the constructs expressing S53A,
S53/116A, and S53D core protein mutants displayed staining patterns similar to that of the wild-type core protein (data not shown).
FIG. 10. Confocal microscopy of Huh7 cells that expressed both core and E1 proteins. Panels (A), (D), and (G), cells transfected with
pCDEF/HA-RCE; (B), (E), and (H), cells transfected with pHA-RC(S116A)E; (C), (F), and (I), cells transfected with pHA-RC(S116D)E. (A), (B), and (C), the
core protein staining using the rabbit anti-core antibody (red color); (D), (E), and (F), the E1 protein staining using a mouse monoclonal anti-E1 antibody
(gift of Dr. M. Selby) (green color); (G), (H), and (I), the superimposed images of core and E1 stainings (yellow color indicates colocalization of core
and E1).
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S53D (data not shown) and the S53/116D double mutant
were also found to localize to the cytoplasm, S116D was
enriched in the nucleus (Fig. 9B). These staining results
were also confirmed by the subcellular fractionation ex-
periment. As shown in Fig. 9A, the wild-type core protein
and other core protein mutants were found mostly in the
cytoplasmic fraction, whereas S116D was found in a
significant amount in the nuclear fraction. In this subcel-
lular fractionation experiment, GRP78, which is a cyto-
plasmic protein associated with membranes, and Ku, a
nuclear protein, were used as the fractionation controls.
Both GRP78 and Ku were found predominantly in their
respective subcellular fractions, indicating that our frac-
tionation procedures appropriately separated cytoplas-
mic and nuclear proteins. The nuclear localization of
S116D was also not due to its association with the
nuclear envelope, as S116D was found in the nucleus of
different sections of the same cell when it was examined
by confocal microscopy (data not shown). The coexpres-
sion of the wild-type core protein with its downstream E1
envelope protein in Huh7 cells resulted in their colocal-
ization in the cytoplasm (Fig. 10). This is consistent with
the previous finding that these two proteins could bind to
each other (Lo et al., 1996). The S116A core protein was
similarly colocalized with the E1 protein in the cytoplasm
(Fig. 10). The S116D core protein, in contrast, remained
enriched in the nucleus (Fig. 10), with an increase of its
appearance in the cytoplasm in the presence of E1 (data
no shown). Thus, our results indicated that the phosphor-
ylation of the core protein at serine-116 likely played an
important role for the nuclear localization of the core
protein.
DISCUSSION
Previous expression studies of a truncated HCV core
protein in insect cells suggested that the HCV core
protein might be a phosphoprotein (Lanford et al., 1993).
By performing the in vitro phosphorylation studies, the
HCV core protein was found to be a substrate of PKC and
PKA (Shih et al., 1995). However, whether the HCV core
protein is indeed a phosphoprotein in mammalian cells
was unclear. In this article, we demonstrated that the
HCV core protein could be phosphorylated in Huh7 (Fig.
1) and HepG2 cells (data not shown), and this phosphor-
ylation is independent of its downstream E1 envelope
protein sequence (Fig. 2). Although the HCV core protein
could be phosphorylated in Huh7 and HepG2 cells, the
efficiency appeared to be low. Based on the relative ratio
of 32P-labeled and 35S-labeled core proteins, the phos-
phorylation efficiency for the HCV core protein was de-
termined to be 30 times lower than that of the HBV core
protein (Fig. 3). Thus, it is conceivable that only a small
fraction of the HCV core protein was phosphorylated in
these liver-derived cell lines.
The possibility that the HCV core protein could be
phosphorylated by PKC was supported by the observa-
tion that the PKC inhibitor calphostin C could reduce the
basal phosphorylation level of the core protein and the
PKC activator PMA could enhance it (Fig. 4). Similarly, our
results also indicated that PKA could phosphorylate the
core protein as its activator forskolin could enhance the
phosphorylation of the core protein and its inhibitor H-89
could abolish this enhancement (Fig. 5). Note that our
results did not rule out the possibility that the core
protein was phosphorylated by the downstream kinases
of PKC and PKA.
The mutagenesis experiment indicated that serine-53
and serine-116 were the two major PKC phosphorylation
sites, as their simultaneous mutations to alanine abol-
ished the phosphorylation of the core protein induced by
PMA (Fig. 7). These results were different from the in
vitro results of Shih et al. (1995), who found that serine-53
and serine-99 were the two major PKC sites. Although
serine-99 also resides in a sequence that is homologous
to the PKC recognition motif (Fig. 6A), our finding that its
mutation had little effect on the core protein phosphory-
lation in Huh7 cells with or without the PMA treatment
does not support a role of this serine residue in the
phosphorylation of the core protein. Thus, our results
underscore the importance of conducting the phosphor-
ylation studies in cell cultures.
By performing similar mutagenesis experiments, we
demonstrated that serine-116 was the major phosphory-
lation site inducible by forskolin (Fig. 8). The role of
serine-53 in the forskolin-induced phosphorylation was
likely minor. Shih et al. demonstrated in their in vitro
studies that serine-53 and serine-116 were the minor and
major phosphorylation sites, respectively, of PKA. Our
results shown in Fig. 8 were thus consistent with their
results.
The double mutation of serine-53 and serine-116 re-
duced the basal phosphorylation level of the core protein
significantly (Figs. 7B and 8B). This result indicates that
serine-53 and serine-116 are two of the major phosphor-
ylation sites in the core protein sequence. Since this
double mutation did not completely abolish the phos-
phorylation of the core protein, there is likely additional
basal phosphorylation site(s) in the core protein se-
quence. This additional site(s) is unlikely recognized by
PKC or PKA, because the S53/116A double mutation
abolished almost entirely the phosphorylation induced
by PKC and PKA activators.
The core protein is found predominantly in the cyto-
plasm in association with the membranes. However, a
small amount of the core protein apparently with a dif-
ferent conformation has also been detected in the nu-
cleus (Yasui et al., 1998). By using the core protein mu-
tants that contained the serine-to-alanine mutation to
mimic dephosphorylation and serine-to-aspartic acid
mutation to mimic phosphorylation, we have examined
the possible effect of phosphorylation on the subcellular
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localization of the core protein. The dephosphorylated
analogs displayed a predominant cytoplasmic staining
pattern resembling that of the wild-type core protein (Fig.
9). This result is perhaps not surprising, as our results
indicated that the majority of the core protein molecules
inside Huh7 cells were likely not phosphorylated. While
the S53D phosphorylated analog was also found pre-
dominantly in the cytoplasm (data not shown), S116D
was found to be enriched in the nucleus (Figs. 9 and 10).
This result indicated that the phosphorylation of the core
protein at serine-116 could stimulate the nuclear local-
ization of the core protein. This was unlikely due to the
effect on the proteolytic cleavage of the core protein,
because the S116D mutation did not apparently affect the
cleavage of the core protein for the production of p19c
(Fig. 9; also data not shown). It was perhaps more likely
due to the alteration of the core protein conformation,
which then activated its nuclear localization signal. Since
the S53/116D double mutant was localized predomi-
nantly to the cytoplasm, the phosphorylation of serine-53
apparently suppressed the nuclear localization of the
core protein stimulated by the phosphorylation of serine-
116. Shih et al. (1995) previously reported that S116D was
localized to the cytoplasm 3 days after transfection of its
expression plasmid into Huh7 cells and was localized to
the nucleus 6 days posttransfection. Therefore their re-
sults contradicted with ours. We do not know the reason
for this discrepancy. However, they also observed the
same results with the wild-type HCV core protein, which
thus far could not be confirmed by other laboratories.
The core protein has multiple functions. Our finding
that the phosphorylation of serine-116 could enhance its
nuclear localization will now allow us to further dissect
the functions of the nuclear core protein. It will be inter-
esting to determine whether the S116D phosphorylation
analog possesses a subset of the core protein functions
such as stimulating the formation of the capsid particle
and/or regulating the cellular gene expression.
MATERIALS AND METHODS
DNA plasmids
The core protein sequence used in this article was
derived from the HCV-RH strain (Lo et al., 1994). The
full-length core protein coding sequence was isolated by
the polymerase chain reaction (PCR) using the sense
primer 5 CCCCAAGCTTACATTTGCTTCTGACACAA-
CTGTGTTCACTAGCAACCTCAAACAGACACCATGTA-
CCCATACGACGTCCCAGACTACGCTAGCACGAATCCTA-
AACCT 3, and the antisense primer 5 GAGTTGCG-
GAATTCTTAGGCCGAA 3. In the sense primer, the
sequence underlined is the coding sequence of the HA-
tag, which is an antigenic epitope derived from the influ-
enza virus hemagglutinin protein. The sequence 3 to the
HA-tag is the core protein coding sequence starting after
the initiation codon, and the sequence 5 to the HA-tag is
derived from the 5-noncoding region of the -globin
gene. The italic letters indicate the HindIII restriction site.
In the antisense primer, the sequence underlined indi-
cates the termination codon introduced at the end of the
core protein sequence, and the italic letters indicate the
EcoRI site. This HA-tagged core protein sequence was
inserted into the HindIII and the EcoRI sites of the pCDEF
vector (Kim et al., 1993) to generate the plasmid pCDEF/
HA-RC. The expression of the HA-core protein sequence
in this plasmid was under the control of the EF1 gene
promoter. pHA-RC(S53A), pHA-RC(S53D), pHA-RC(S99A),
pHA-RC(S116A), and pHA-RC(S116D) were identical to
pCDEF/HA-RC except that their respective serine
codons at position 53, 99, or 116 had been mutated to the
codon of alanine or aspartic acid. In addition, pHA-
RC(S53A) and pHA-RC(S53D) were cloned into the
HindIII/BamHI site of pCDEF. The serine codons were
changed to GCC for S53A, GAC for S53D, GCT for S99A,
GCG for S116A, and GAC for S116D. pHA-RC(S53/116A)
and pHA-RC(S53/116D) were also identical to pCDEF/
HA-RC, except that in these two plasmids, serine-53 and
serine-116 codons were both mutated to alanine and
aspartic acid codons, respectively. In these two plas-
mids, the HA-tagged core protein sequence was cloned
into the HindIII/BamHI site of the pCDEF vector. The
nucleotide sequences of the above DNA constructs were
confirmed by direct sequencing at the University of
Southern California Microchemical Core Facility. pCDEF/
HA-RCE was constructed by joining the 550-bp HindIII/
BstXI fragment from pCDEF/HA-RC to the 850-bp BstXI/
XbaI fragment of pCMV-CCE (Lo et al., 1996) followed
by insertion into the HindIII/XbaI site of the pCDEF vec-
tor. This plasmid contained nucleotides (nt) 1–1191 of the
HCV-RH coding sequence, which contained the entire
coding sequence of the core protein, the E1 envelope
protein, and the first 48 codons of the E2 protein. pHA-
RC(S116A)E and pHA-RC(S116D)E were identical to pC-
DEF/HA-RCE except that the serine-116 codon in the
core protein sequence has been mutated to the alanine
codon and the aspartic acid codon, respectively.
Kinase inhibitors and activators
The PKC inhibitors calphostin C (CalC) and Ro-31-8220
and the PKA inhibitor H-89 and activator forskolin were
purchased from Calbiochem-Novabiochem Co. (San Di-
ego, CA). The PKC activator PMA was purchased from
Aldrich Chemical Co. (St. Louis, MO). All these chemicals
were dissolved in dimethyl sulfoxide (DMSO). DMSO
was used as a reagent control when these chemicals
were used to study the phosphorylation of the core
protein.
DNA transfection and phosphorylation studies
Huh7 cells and HepG2 cells were maintained in Dul-
becco’s modified Eagle’s medium (DMEM) containing
28 LU AND OU
10% fetal bovine serum (FBS). Cells at 70% confluency in
a 10-cm petri dish were transfected with 20 g of the
core protein expressing plasmid using the CaPO4 pre-
cipitation method (Lu et al., 1999). pXGH5 (Nichols Diag-
nostic), a plasmid that expressed the human growth
hormone (hGH), was used for cotransfection to monitor
the transfection efficiency. Whether pXGH5 was included
in the cotransfection experiment or not did not affect the
phosphorylation of the core protein (data not shown). For
phosphorylation studies, cells were split into two 60-mm
dishes 24 h after transfection. After the incubation for
another 16 h, one plate of the cells was incubated with
the phosphate-free medium containing 10% dialyzed FBS
for 2–3 h and labeled with 32P-orthophosphate at a con-
centration of 0.25 mCi/ml for 4 h. Depending on the
experiments, cells were treated with different amounts of
kinase activators or inhibitors for different lengths of time
as specified in the figure legends during 32P-labeling.
After labeling, cells were rinsed twice with phosphate-
buffered saline (PBS), lysed with 1 ml of the radioimmu-
noprecipitation assay (RIPA) buffer (Lo et al., 1996) con-
taining 1 mM PMSF, and immunoprecipitated with 2 l of
the mouse monoclonal anti-HA antibody (1 mg/ml). The
immunoprecipitates were analyzed on a 11% SDS–PAGE
gel. The other plate of cells was used for Western blot
analysis. For this plate, cells were lysed with RIPA con-
taining 1 mM PMSF followed by sonication to shear the
chromosomal DNA. Equal amounts of protein samples
were then separated on an 11% SDS–PAGE gel. The
primary antibody used was the rabbit anticore antibody
(Lo et al., 1995; Lu et al., 1999) and the secondary anti-
body used was the horseradish peroxidase (HRP)-con-
jugated goat anti-rabbit antibody (Pierce, Rockford, IL).
The Western blot signals were developed by chemilumi-
nescence using an ECL kit purchased from Pierce. Al-
ternatively, this second plate might also be starved with
methionine-free media for 3 h, followed by radiolabeling
with [35S]methionine (0.1 mCi/ml) for 1 h. Cells were then
lysed for radioimmunoprecipitation as described above
or in the figure legends.
Quantification of the core protein phosphorylation
The relative core protein phosphorylation levels in-
duced or suppressed by various activators or inhibitors
were calculated by the following equation:
Relative phosphorylation signal
[(P1 Pc)/(W1Wc)]
[(P0 Pc)/(W0Wc)]
where P0 and P1 were the core protein phosphorylation
signals immunoprecipitated from the cells treated with
DMSO and the inhibitor (or activator), respectively. The
phosphorylation signals of the core protein bands were
measured by a PhosphorImager (Molecular Dynamics).
Pc was the background signal measured from the same
area of control lanes on the same autoradiogram. W0
and W1 were the core protein signals obtained from the
Western blot analysis. These signals on the X-ray films
were measured by densitometry. Wc was the back-
ground signal measured from the same locations of the
control lanes. The results represented the average of at
least three independent transfection experiments.
Subcellular fractionation
Huh7 cells in a 10-cm dish were scraped off the plates
in Tris-buffered saline (TBS; 10 mM Tris–HCl, pH 7.0, 150
mM NaCl), pelleted at 1500 g for 2 min in a microcentri-
fuge, resuspended in 150 l ice-cold Buffer A (10 mM
HEPES–KOH, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM
DTT, 1 mM PMSF), and sat on ice for 20 min. This
hypotonic treatment caused the cells to rupture. The cell
lysates were then fractionated by centrifugation at 1500 g
for 2 min. The supernatant of the Buffer A lysates was
saved and transferred to a new tube. The pellet, which
contained the nuclei, was resuspended in 50 l ice-cold
Buffer B (20 mM HEPES–KOH, pH 7.9, 25% glycerol, 420
mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 1
mM PMSF), incubated on ice for 30 min, and centrifuged
at 15,000 g for 5 min. The supernatant, which was the
nuclear lysates, was recovered. The pellet was resus-
pended in the saved Buffer A supernatant plus 1% Non-
idet P-40 (NP-40) and incubated on ice for 10 min. The
mixture was then centrifuged at 15,000 g for 5 min for the
isolation of the cytoplasmic lysates. Five microliters of
nuclear lysates and 7.5 l of cytoplasmic lysates pre-
pared this way were subjected to electrophoresis on a
12.5% SDS–PAGE gel and Western-blotted using the rab-
bit anticore antibody.
Immunofluorescence staining and confocal
microscopy
Huh7 cells were seeded on a coverslip in a six-well
dish and transfected with various DNA constructs. Forty-
four hours after transfection, cells were fixed with ace-
tone at 20°C for 3 min. HCV core proteins were de-
tected by indirect immunofluorescence staining using
the rabbit anticore antibody (1:400 dilution) as the pri-
mary antibody and the fluorescein isothiocyanate (FITC)-
conjugated goat anti-rabbit antibody (1:100 dilution) as
the secondary antibody (Boehringer Mannheim). For the
confocal microscopy, different sections of the cells were
examined with a Nikon confocal microscope. For the
double staining of core and E1 proteins, the core protein
was stained with the rabbit anti-core primary antibody
(1:200 dilution) and the rhodamine isothiocyanate (RITC)-
conjugated goat anti-rabbit secondary antibody (1:100
dilution). The E1 envelope protein was stained with the
mouse monoclonal anti-E1 primary antibody (a gift of Dr.
M. Selby, Chiron Corp.) and the FITC-conjugated goat
anti-mouse secondary antibody.
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